Jun. 11 at 11:26 AM
Shares of U.S based
$INSM surged +28.65% on Tuesday at
$90.93, after the global biopharmaceutical company announced positive results from a Phase 2b study of treprostinil palmitil inhalation powder, a once-daily treatment for pulmonary arterial hypertension. U.S. based
$UTHR fell in turn, dropping -14.32% at
$281.36. Insmed stock is up +38.59% in the past month, +31.71% in 2205 & +47.49% y/y, with a market cap of
$16.56B. United Therapeutics shares are down -6.11% in the past month, -20.26% in 2025 & -0.18% y/y, with a market cap of
$12.69B.